PMID- 21822560
OWN - NLM
STAT- MEDLINE
DCOM- 20120816
LR  - 20210103
IS  - 1534-4681 (Electronic)
IS  - 1068-9265 (Linking)
VI  - 19
IP  - 5
DP  - 2012 May
TI  - The immunological impact of neoadjuvant chemotherapy on the tumor 
      microenvironment of esophageal squamous cell carcinoma.
PG  - 1713-9
LID - 10.1245/s10434-011-1906-x [doi]
AB  - BACKGROUND: Esophageal cancer is an aggressive cancer with poor prognosis. 
      However, little is known about the immune response in the tumor microenvironment 
      after neoadjuvant chemotherapy. PURPOSE: To investigate the immunological impact 
      of neoadjuvant chemotherapy in the tumor microenvironment of esophageal squamous 
      cell carcinoma. METHODS: Eighteen patients with esophageal squamous cell 
      carcinoma with and without neoadjuvant chemotherapy were analyzed using 
      immunohistochemical methods for human leukocyte antigen (HLA) class I heavy 
      chain, CD4-, CD8-, and Foxp3-positive cell infiltration. RESULTS: The number of 
      CD4 T cells in the stroma and within the cancer nest was significantly higher in 
      the neoadjuvant chemotherapy group. The number of CD8 T cells in the stroma was 
      significantly higher in the neoadjuvant chemotherapy group. HLA class I 
      expression was more downregulated in the control group compared with the 
      neoadjuvant chemotherapy group. CONCLUSION: Neoadjuvant chemotherapy utilizing 
      5-fluorouracil and cisplatin in esophageal squamous cell carcinoma is useful to 
      induce CD4 and CD8 T lymphocytes in the tumor microenvironment and to maintain 
      HLA class I expression levels in combination with its direct cytotoxic effects.
FAU - Tsuchikawa, Takahiro
AU  - Tsuchikawa T
AD  - Department of Surgical Oncology, Division of Surgery, Hokkaido University 
      Graduate School of Medicine, Sapporo, Japan. tsuchi-t@med.hokudai.ac.jp
FAU - Miyamoto, Masaki
AU  - Miyamoto M
FAU - Yamamura, Yoshiyuki
AU  - Yamamura Y
FAU - Shichinohe, Toshiaki
AU  - Shichinohe T
FAU - Hirano, Satoshi
AU  - Hirano S
FAU - Kondo, Satoshi
AU  - Kondo S
LA  - eng
PT  - Journal Article
DEP - 20110806
PL  - United States
TA  - Ann Surg Oncol
JT  - Annals of surgical oncology
JID - 9420840
RN  - 0 (FOXP3 protein, human)
RN  - 0 (Forkhead Transcription Factors)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - Q20Q21Q62J (Cisplatin)
RN  - U3P01618RT (Fluorouracil)
SB  - IM
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - CD8-Positive T-Lymphocytes/immunology
MH  - Carcinoma, Squamous Cell/*drug therapy/*immunology/mortality/pathology/surgery
MH  - Chemotherapy, Adjuvant
MH  - Cisplatin/administration & dosage
MH  - Esophageal Neoplasms/*drug therapy/*immunology/mortality/pathology/surgery
MH  - Esophagectomy
MH  - Female
MH  - Fluorouracil/administration & dosage
MH  - Forkhead Transcription Factors/immunology
MH  - Histocompatibility Antigens Class I/immunology
MH  - Humans
MH  - Lymphocytes, Tumor-Infiltrating/*immunology
MH  - Male
MH  - Middle Aged
MH  - Neoadjuvant Therapy
MH  - Neoplasm Staging
MH  - Survival Rate
MH  - Tumor Microenvironment
EDAT- 2011/08/09 06:00
MHDA- 2012/08/17 06:00
CRDT- 2011/08/09 06:00
PHST- 2011/03/09 00:00 [received]
PHST- 2011/08/09 06:00 [entrez]
PHST- 2011/08/09 06:00 [pubmed]
PHST- 2012/08/17 06:00 [medline]
AID - 10.1245/s10434-011-1906-x [doi]
PST - ppublish
SO  - Ann Surg Oncol. 2012 May;19(5):1713-9. doi: 10.1245/s10434-011-1906-x. Epub 2011 
      Aug 6.